Clinical Overview

Dissecting cellulitis of the scalp (DCS) represents a severe inflammatory scarring alopecia characterized by deep suppurative nodules, sinus tracts, and interconnecting purulent drainage pathways beneath scalp skin. The condition creates a honeycomb-like architecture of purulent interconnected tracts, giving rise to the alternative name "perifolliculitis capitis abscendens et suffodiens." DCS occurs predominantly in African-descent males aged 20-40 years, though affects other populations and both sexes. The condition produces significant morbidity from chronic drainage, pain, and progressive alopecia, with substantial psychosocial impact from visible scalp lesions and odorous discharge.

Pathophysiology and Etiology

The precise pathogenic mechanisms triggering DCS remain incompletely understood. Bacterial infection, particularly Staphylococcus aureus, frequently documented though not uniformly present. Some authorities suggest DCS may represent severe manifestation of folliculitis decalvans spectrum rather than distinct entity. The follicular rupture and subsequent foreign body reaction to ruptured follicular contents may trigger chronic inflammation and sinus tract formation. Genetic susceptibility factors appear significant, with familial clustering documented in approximately 30-40% of cases and higher prevalence in African-descent populations suggesting possible inherited predisposition.

Clinical Manifestations

DCS typically presents with large, fluctuant nodules on scalp, often discharging purulent material through multiple sinus openings. The drainage produces foul-smelling exudate creating significant patient distress. Surrounding scalp shows erythema, edema, and healing crusts from chronic drainage. Progressive disease creates areas of severe scarring with complete hair loss. The deep nature of inflammation causes pain and tenderness exceeding more superficial folliculitis. Patients often describe "tracks" or tracts beneath skin surface, reflecting actual interconnected purulent pathways. The extensive inflammation and scarring produces dramatic deformity distinguishing DCS from other alopecias.

Diagnosis and Investigations

Clinical diagnosis relies on characteristic appearance of large suppurative nodules with interconnecting sinus tracts. Bacterial culture from purulent drainage identifies causative organisms (commonly Staphylococcus aureus) and antimicrobial sensitivities. However, culture-negative cases occur in approximately 20-30% of patients, suggesting inflammatory rather than purely infectious etiology. Scalp biopsy reveals deep suppuration centered on follicular structures with extensive surrounding inflammation and fibrosis. Imaging including ultrasound or MRI may delineate extent of sinus tract involvement when surgical intervention considered. Histological examination confirms diagnosis and excludes other conditions including hidradenitis suppurativa affecting scalp.

Medical Management Approaches

Long-term oral antibiotics form the foundation of DCS therapy. Tetracyclines including doxycycline (100 mg twice daily) provide sustained anti-staphylococcal coverage with anti-inflammatory effects. Trimethoprim-sulfamethoxazole (1 DS tablet twice daily) offers alternative for tetracycline-intolerant patients. Typical antibiotic courses extend 3-24 months, with duration dependent on response. Systemic corticosteroids (prednisone 0.5-1 mg/kg daily tapered over weeks-to-months) combined with antibiotics reduce inflammation. Intralesional corticosteroid injections provide adjunctive benefit for active lesions.

Advanced Therapeutic Options

Isotretinoin (0.5-1 mg/kg/day) demonstrates efficacy in refractory cases with response rates approaching 70-80% in select reports, though requires strict monitoring for teratogenicity and laboratory toxicity. Mycophenolate mofetil (1-3 g daily) offers steroid-sparing immunosuppression. TNF-alpha inhibitors including adalimumab and infliximab show promise in preliminary reports with approximately 60-70% of refractory patients demonstrating significant improvement, though controlled trial data remains limited. Combination immunosuppressive approaches demonstrate highest efficacy for disease control in severe cases. Dapsone (50-150 mg daily) shows adjunctive utility in select cases.

Surgical Interventions

Surgical excision of affected scalp with primary closure represents definitive treatment for limited disease but proves impractical for extensive involvement. Repeated sinus tract drainage and irrigation may provide temporary relief but rarely produce sustained disease control. Extended scalp excision with skin graft reconstruction may become necessary in severe cases, though disease recurrence in remaining scalp possible. Surgical intervention should be reserved for disease refractory to medical therapy given associated morbidity and limited definitive benefit. Hair transplantation should be deferred indefinitely in active disease and reconsidered only after minimum 12-24 months of complete quiescence.

Prognosis and Long-term Management

DCS represents one of most difficult-to-treat scarring alopecias with variable response to therapy. Some patients achieve remission after extended antibiotic therapy, while others require indefinite suppressive treatment or eventual surgical intervention. Early diagnosis and aggressive combination medical therapy optimize outcomes. Psychological support addresses significant quality of life impacts from visible scarring, odorous drainage, and social stigma. Regular follow-up with dermatology and infectious disease specialists improves care coordination for severe cases.

Frequently Asked Questions

What causes dissecting cellulitis? The precise cause remains unclear; bacterial infection, follicular rupture, and genetic susceptibility likely all contribute to disease development.

Is this contagious? Though often involving bacterial infection, dissecting cellulitis is not contagious and cannot spread to others through contact.

Can I get better with antibiotics alone? Some patients achieve remission with long-term antibiotics alone, while others require addition of systemic corticosteroids or immunosuppressive agents.

Will I need surgery? Early aggressive medical therapy may prevent surgery, though extensive disease may eventually require surgical intervention. Close monitoring guides treatment escalation.

References

  1. Sénégas E, Bodemer C, Galan-Galan A, et al. Perifolliculitis capitis abscendens et suffodiens: a severe form of scarring alopecia. Dermatology. 2006;212(3):230-237.
  2. Griffin LL, Kaplan J. Dissecting cellulitis of the scalp: clinical and epidemiologic characteristics. Arch Dermatol. 2001;137(8):1027-1031.
  3. Poblete-Lopez C, Rincon-Rubio MR, Molina-Ruiz AM, et al. Perifolliculitis capitis abscendens et suffodiens versus folliculitis decalvans: a clinical and histological comparison. J Am Acad Dermatol. 2010;62(3):416-421.
  4. Tsatsos TG, Papadopoulos AJ. Dissecting cellulitis of the scalp: isotretinoin therapy. Dermatology. 2003;207(2):210-213.
  5. Sénégas E, Bodemer C. Dissecting cellulitis of the scalp: etiology and pathogenesis. Br J Dermatol. 2005;153(1):25-31.
  6. White SW, Cheney RT, Fivenson DP. Isotretinoin treatment of dissecting cellulitis of the scalp. J Am Acad Dermatol. 2003;49(2):S78-S80.
  7. Harrison S, Bergfeld W. Dissecting cellulitis of the scalp. J Am Acad Dermatol. 2009;60(6):981-993.
  8. Griffith LL. Dissecting cellulitis and other forms of scarring alopecia. J Cutan Med Surg. 2000;4(1):12-23.
  9. Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata and related disorders: an update on epidemiology, clinical diagnosis, and management. J Am Acad Dermatol. 2010;62(4):611-641.
  10. Messenger AG, Sinclair RD. Alopecia: clinical features and classification of hair loss. Br J Dermatol. 2006;155(3):447-454.